Results from ENLIGHTEN 1 Phase 3 Extension Stage support LYR-210's favorable safety profile and general consistency with the Primary Study Phase in patients with CRS In the CRS patient subgroup with ...
- First product candidate found to be effective in non-polyp patients in addition to polyp patients in a clinical trial, based on 100% of patients in both groups achieving SNOT-22 MCID at week 24 with ...
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory ...
Lyra reported positive topline data from the LANTERN study in December 2020. The COSM oral presentation, titled Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results